Publicaciones - IR Sant Pau

Buscar

01/10/2024 Basal Circulating Leukocyte-Platelet Complexes and PD-L1 Expression on Circulating Cells in Patients with Advanced SCLC

Piedra, A, Guinart-Cuadra, A, Mulet, M, Zamora, C, Alejandre, J, Martínez-Recio, S, Barba, A, Sullivan, I, Serra-López, J, Isla, D, Arriola, E, Paz-Ares, L, Diz, MP, Moreno, AL, Callejo, A, Vidal, S, Majem, M. Basal Circulating Leukocyte-Platelet Complexes and PD-L1 Expression on Circulating Cells in Patients with Advanced SCLC. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

01/10/2024 Five-Year Clinical Outcomes of Perioperative Nivolumab and Chemotherapy in Stage III Non-SmallCell Lung Cancer (NADIM Trial)

Provencio, M, Nadal, E, Insa, A, Campelo, MRG, Calvo, V, Palmero, R, Lázaro, M, Dómine, M, Majem, M, Rodríguez-Abreu, D, Martínez-Martí, A, Carpeño, JDC, Cobo, M, Bernabé, R, Viñolas, N, Barneto, I, Viteri, S, Cruz-Bermudez, A, Romero, A, Massutí, B. Five-Year Clinical Outcomes of Perioperative Nivolumab and Chemotherapy in Stage III Non-SmallCell Lung Cancer (NADIM Trial). Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

01/10/2024 Patterns of Disease Progression after Atezolizumab Plus Chemotherapy in ES-SCLC: Exploratory Analysis from IMfirst Study

Garcia-Campelo, R, Gómez, MD, de Castro, J, Vega, AM, Aix, SP, Arriola, E, Carcereny, E, Majem, M, Vence, GH, González, EE, Pradera, JF, Granados, ALO, Morales, MG, Sureda, BM, Núñez, NF, Provencio, M, González-Mancha, N, Fajardo, CA, Lerones, N, Dols, MC. Patterns of Disease Progression after Atezolizumab Plus Chemotherapy in ES-SCLC: Exploratory Analysis from IMfirst Study. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

01/10/2024 TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials

Martínez-Toledo, C, Sierra, B, Molina-Alejandre, M, Casarrubios, M, Calvo, V, Nadal, E, Campelo, MRG, Martínez-Martí, A, Garrido, A, Massutí, B, Insa, A, De Castro, J, Dóomine, M, González-Larriba, JL, Majem, M, Ponce, S, Barneto, I, Aguilar, A, Martín-López, J, Provencio, M, Cruz-Bermúdez, A. TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

01/10/2024 Volrustomig plus platinum doublet chemotherapy (CTx) in first-line non-small cell lung cancer (NSCLC): Phase 1b trial update

Spigel, DR, Ahn, MJ, Majem, M, Rodríguez, LM, Lee, KH, Carcereny, E, Hernández, AA, Insa, A, Cho, EK, Besse, B, Rha, SY, Weiss, J, D'Arcangelo, M, Im, SA, Kim, SW, Carneiro, BA, Gadgeel, SM, Mitchell, P, Asare, JM, Gainer, SD, Achour, I, Subramaniam, DS, Felip, E. Volrustomig plus platinum doublet chemotherapy (CTx) in first-line non-small cell lung cancer (NSCLC): Phase 1b trial update. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

01/10/2024 Amivantamab Plus Lazertinib vs Osimertinib in First Line, EGFR-Mutant Advanced NSCLC: Patientrelevant Outcomes from MARIPOSA

Nguyen, D, Besse, B, Cho, BC, Lee, SH, Lee, KH, Lu, S, Cheng, Y, Yao, Y, Girard, N, Lin, CC, Felip, E, Aguilar, A, Charoentum, C, Cruz, FJSM, Majem, M, Lim, CS, Akamatsu, H, Hayashi, H, Yang, JCH, Kowalyszyn, R, Tiscoski, K, Franke, F, Ponomarenko, D, Arslan, C, Forster, M, Urban, D, Misch, D, Delmonte, A, Montes, LVG, Gadgeel, SM, Cruz-Correa, M, Peguero, J, Rousey, S, Gaffar, Y, Owen, S, Schuchard, J, Diels, J, Sermon, J, Sun, T, Ennis, M, Fennema, E, Daksh, M, Sethi, S, Bauml, JM, Campelo, MRG. Amivantamab Plus Lazertinib vs Osimertinib in First Line, EGFR-Mutant Advanced NSCLC: Patientrelevant Outcomes from MARIPOSA. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

01/09/2024 Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

Rodriguez-Vida, A, Valderrama, BP, Castellano, D, Pinto, A, Mellado, B, Puente, J, Climent, MA, Domenech, M, Vazquez, F, Perez-Gracia, JL, Bonfill, T, Morales-Barrera, R, Gonzalez-Billalabeitia, E, Garcia-del-Muro, X, Maroto, P, Navarro-Gorro, N, Juanpere, N, Juan, O, Bellmunt, J. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study. ESMO Open. 2024; 9(9)DOI:10.1016/j.esmoop.2024.103690. PMID:39214051. IF:8.300(Q1/2D).

20/08/2024 Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study

Tibau, A, Hwang, TJ, Avorn, J, Kesselheim, AS. Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study. BMJ-British Medical Journal. 2024; 386DOI:10.1136/bmj-2023-079126. PMID:39164034. IF:42.700(Q1/1D).

15/07/2024 Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer

Peressini, M, Garcia-Campelo, R, Massuti, B, Marti, C, Cobo, M, Gutiérrez, V, Dómine, M, Fuentes, J, Majem, M, de Castro, J, Córdoba, JF, Diz, MP, Isla, D, Esteban, E, Carcereny, E, Vila, L, Moreno-Vega, A, Ros, S, Moreno, A, García, FJ, Huidobro, G, Aguado, C, Cebey-López, V, Valdivia, J, Palmero, R, Lianes, P, López-Brea, M, Vidal, OJ, Provencio, M, Arriola, E, Baena, J, Herrera, M, Bote, H, Molero, M, Adradas, V, Ponce-Aix, S, Nuñez-Buiza, A, Ucero, A, Hernandez, S, Lopez-Rios, F, Conde, E, Paz-Ares, L, Zugazagoitia, J. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer. CLINICAL CANCER RESEARCH. 2024; 30(14)DOI:10.1158/1078-0432.CCR-24-0104. PMID:38630755. IF:10.200(Q1/1D).

04/07/2024 SpadaHC: a database to improve the classification of variants in hereditary cancer genes in the Spanish population

Moreno-Cabrera, JM, Feliubadaló, L, Pineda, M, Prada-Dacasa, P, Ramos-Muntada, M, Del Valle, J, Brunet, J, Gel, B, Currás-Freixes, M, Calsina, B, Salazar-Hidalgo, ME, Rodríguez-Balada, M, Roig, B, Fernández-Castillejo, S, Domínguez, M, Ledo, M, Sanz, MI, Castillejo, A, Dámaso, E, Soto, JL, de Miguel, M, Calero, B, Sánchez-Zapardiel, JM, Ramon, T, Lasa, A, Gisbert-Beamud, A, López-Novo, A, Ruiz-Ponte, C, Potrony, M, Alvarez-Mora, M, Osorio, A, Lorda-Sánchez, I, Robledo, M, Cascon, A, Ruiz, A, Spataro, N, Hernan, I, Borràs, E, Moles-Fernández, A, Earl, J, Cadiñanos, J, Sánchez-Heras, AB, Bigas, A, Capellá, G, Lazaro, C. SpadaHC: a database to improve the classification of variants in hereditary cancer genes in the Spanish population. Database-The Journal of Biological Databases and Curation. 2024; 2024DOI:10.1093/database/baae055. PMID:38965703. IF:3.600(Q1/1D).

10/06/2024 KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.

Gregorc, V, González-Cao, M, Salvagni, S, Koumarianou, A, Gil-Bazo, I, Maio, M, Viteri, S, Majem, M, Gutiérrez, V, Caro, RB, Sanmamed, MF, Zhu, HQ, Shen, HG, Wang, Y, Rosell, R. KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(17_SUPPL)DOI:10.1200/JCO.2024.42.17_suppl.LBA8511. PMID:. IF:41.900(Q1/1D).

01/06/2024 Global cooperation and early access-clinical outcomes matter

Tibau, A, Kesselheim, AS. Global cooperation and early access-clinical outcomes matter. LANCET ONCOLOGY. 2024; 25(6)DOI:10.1016/S1470-2045(24)00210-9. PMID:38754452. IF:35.900(Q1/1D).

01/06/2024 Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM)

Gately, L, Mesía, C, Sepúlveda, JM, del Barco, S, Pineda, E, Gironés, R, Fuster, J, Dumas, M, Gill, S, Navarro, LM, Herrero, A, Dowling, A, de las Peñas, R, Vaz, MA, Alonso, M, Lwin, Z, Harrup, R, Peralta, S, Long, A, Perez-Segura, P, Ahern, E, Garate, CO, Wong, M, Campbell, R, Cuff, K, Jennens, R, Gallego, O, Underhill, C, Martinez-Garcia, M, Covela, M, Cooper, A, Brown, S, Rosenthal, M, Torres, J, Collins, IM, Gibbs, P, Balana, C. Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM). JOURNAL OF NEURO-ONCOLOGY. 2024; 168(2)DOI:10.1007/s11060-024-04668-5. PMID:38630385. IF:3.100(Q2/4D).

01/06/2024 Clinical applicability of guideline-recommended molecular targets and genometargeted cancer therapies

Tibau, A, Hwang, TJ, Avorn, J, Kesselheim, AS. Clinical applicability of guideline-recommended molecular targets and genometargeted cancer therapies. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

01/06/2024 Chemotherapy sensitivity in pancreatic neoplasms with PALB2 Gene mutations: First results of PALB2 pancreatic cancer study

Serda, PC, Cullell, BM, Castet, F, Gatell, AP, Fernandez, PR, Fernandez, J, Nadal, TS, Mateo, FJP, Sorolla, MA, Cajal, TRY. Chemotherapy sensitivity in pancreatic neoplasms with PALB2 Gene mutations: First results of PALB2 pancreatic cancer study. ANNALS OF ONCOLOGY. 2024; 35DOI:10.1016/annonc.2024.05.508. PMID:. IF:65.400(Q1/1D).

01/06/2024 Preliminary results correlating post-operative ctDNA status with disease-free survival in patients with stage II (high risk)/III colorectal cancer in the BNT000-001 epidemiology study

Reinacher-Schick, AC, Lopez, MR, Alonso-Orduña, V, Lopez-Bravo, DP, Vergauwe, P, Tannapfel, A, Silveira, AB, Schlombs, K, Young, P, He, Y, Henn, H, Manning, L, Preussner, L, Mueller, F, Sahin, U, Türeci, O. Preliminary results correlating post-operative ctDNA status with disease-free survival in patients with stage II (high risk)/III colorectal cancer in the BNT000-001 epidemiology study. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

01/06/2024 The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families (vol 73, 103611, 2024)

Schreurs, MAC, Cajal, TRY, Adank, MA, Collée, JM, Hollestelle, A, van Rooij, J, Schmidt, MK, Hooning, MJ. The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families (vol 73, 103611, 2024). BREAST. 2024; 75DOI:10.1016/j.breast.2024.103723. PMID:. IF:7.900(Q1/1D).

01/06/2024 Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC)

Aggarwal, C, Martinez-Marti, A, Majem, M, Barlesi, F, Carcereny, E, Chu, QS, Monnet, I, Sanchez, A, Dakhil, SR, Camidge, DR, Pillet, M, Brown, M, Dowson, A, Cooper, ZA, Kumar, R, Herbst, RS. Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

01/06/2024 Real-world effectiveness and safety of dabrafenib-trametinib as first-line of treatment for BRAF mutated metastatic melanoma: Results of the study GEM1801

Berciano-Guerrero, MA, Perez-Ruiz, E, Couselo, EM, Manzano, JL, Cerezuela-Fuentes, P, de Miguel, PA, Soria, A, Castaño, AG, Crespo, G, Puértolas, T, De La Rosa, CA, Sanz, LG, Castro, RL, Espinosa, E, Lecumberri, MJ, Majem, M, Martinez, JM, Bellido, L, Fernández-Morales, LA, Martin-Algarra, S. Real-world effectiveness and safety of dabrafenib-trametinib as first-line of treatment for BRAF mutated metastatic melanoma: Results of the study GEM1801. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

01/06/2024 Circulating tumor DNA (ctDNA) to detect acquired resistance to first-line (1L) treatment of RASWT metastatic colorectal cancer (mCRC): Insights from the PLATFORM-B study

Martelli, V, Barrull, JV, Rodriguez, CF, Alfonso, PG, Paez, D, Gibert, J, Alonso, V, España, MAG, Vivas, CS, Ogalla, GD, Fernandez, MEE, Garcia-Carbonero, R, Monteagudo, RF, Mozo, JLM, Losa, F, Paricio, BB, Tabernero, J, Soler, RS, Aguilar, EA, Viladot, CM. Circulating tumor DNA (ctDNA) to detect acquired resistance to first-line (1L) treatment of RASWT metastatic colorectal cancer (mCRC): Insights from the PLATFORM-B study. ANNALS OF ONCOLOGY. 2024; 35DOI:10.1016/j.annonc.2024.05.121. PMID:. IF:65.400(Q1/1D).

01/06/2024 Patient-reported tolerability of sotorasib (soto) and panitumumab (pani) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in patients (pts) with metastatic colorectal cancer (mCRC) in the CodeBreaK 300 study

Taieb, J, Fakih, M, Salvatore, L, Esaki, T, Modest, DP, Paez, D, Karamouzis, MV, Ruiz, E, Kim, TW, Kuboki, Y, Meriggi, FA, Cunningham, D, Yeh, KH, Cremolini, C, Wang, J, Tran, Q, Chao, J, Chen, Z, Pietrantonio, F. Patient-reported tolerability of sotorasib (soto) and panitumumab (pani) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in patients (pts) with metastatic colorectal cancer (mCRC) in the CodeBreaK 300 study. ANNALS OF ONCOLOGY. 2024; 35DOI:10.1016/j.annonc.2024.05.043. PMID:. IF:65.400(Q1/1D).

01/06/2024 Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC)

John, T, Grohe, C, Goldman, JW, Kato, T, Laktionov, KK, Bonanno, L, Tiseo, M, Majem, M, Domine, M, Ahn, MJ, Perol, M, Hartmaier, R, Robichaux, J, Bhetariya, P, Markovets, A, Rukazenkov, Y, Muldoon, C, Herbst, RS, Tsuboi, M, Wu, YL. Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

01/06/2024 Comprehensive clinical characteristics and ctDNA mutational profile analysis of endocrine resistance/sensitivity to adjuvant ET therapy in luminal breast cancer from the GEICAM/2014-03_RegistEM registry

Guerrero, A, Alvarez, I, Novoa, SA, Jurado, JC, Sanchez, CAR, Martinez, P, Falo, C, Hernández-Sosa, M, Margelí, M, Maeso, IG, Rodríguez-Lescure, A, Alcalá, MM, Anton, A, Ferreiro, SV, Herranz, J, Caballero, R, García, DF, Tibau, A, Cobo, SLT, Todo, FGR. Comprehensive clinical characteristics and ctDNA mutational profile analysis of endocrine resistance/sensitivity to adjuvant ET therapy in luminal breast cancer from the GEICAM/2014-03_RegistEM registry. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

01/06/2024 First-in-human CEB-01: Novel loco-regional SN-38 release membrane to prevent local recurrence in retroperitoneal sarcomas

González-Lopez, JA, Sebio, A, Hindi, N, Jimenez, M, Villarejo-Campos, P, Martin-Broto, J, Díaz-Beveridge, R, Castellanos, JFO, Andújar, RL, Alvarez, RA, Asencio, JM, Serrano, C, Conde, NR, Boix, SC, Gimenez-Salinas, LK, Garcia, JAT, Campos, AP, Lopera, E, Bertran, J, Pousa, AL. First-in-human CEB-01: Novel loco-regional SN-38 release membrane to prevent local recurrence in retroperitoneal sarcomas. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

01/06/2024 Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)

Garassino, MC, Wakelee, HA, Spicer, J, Liberman, M, Kato, T, Tsuboi, M, Lee, SH, Chen, KN, Dooms, CA, Majem, M, Eigendorff, E, Martinengo, GL, Bylicki, O, Rodriguez-Abreu, D, Chaft, JE, Yang, J, Arunachalam, A, Norquist, JM, Keller, SM, Gao, SG. Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).

01/06/2024 Positive ad hoc results from neoadjuvant Foxy-5 treatment of colon cancer patients in the ongoing phase II NeoFox study

Soler, RS, Vivas, CS, Macias, I, Esteban, AY, Bassam, A, Plazas, JG, Al-Farhat, Y, Cervantes, A, Alfonso, PG, Paez, D, Ruiz-Casado, A, Lopez, C, Arkosy, PF, Furka, A, Rodriguez-Salas, N, Pascual, FJR, Gracian, AC, Hitre, E, Monteagudo, RF, Salvia, MAS. Positive ad hoc results from neoadjuvant Foxy-5 treatment of colon cancer patients in the ongoing phase II NeoFox study. ANNALS OF ONCOLOGY. 2024; 35DOI:10.1016/j.annonc.2024.05.020. PMID:. IF:65.400(Q1/1D).

16/05/2024 Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies

Tibau, A, Hwang, TJ, Molto, C, Avorn, J, Kesselheim, AS. Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies. JAMA Oncology. 2024; 10(5)DOI:10.1001/jamaoncol.2024.0194. PMID:38573645. IF:20.100(Q1/1D).

01/05/2024 Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry

Salazar, J, Garcia-Planella, E, Fernández-Clotet, A, Esteve, M, Gisbert, JP, Busquets, D, Lucendo, A, Márquez, L, Guardiola, J, Martín-Arranz, MD, Iglesias, E, Monfort, D, Villoria, A, Cañete, F, Bell, O, Ricart, E, Zabana, Y, Chaparro, M, Domènech, E, Gordillo, J. Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2024; 90(5)DOI:10.1111/bcp.16017. PMID:38369687. IF:3.000(Q2/4D).

01/05/2024 Potential Role of Circulating PD-L1⁺ Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients

Anguera, G, Mulet, M, Zamora, C, Osuna-Gómez, R, Barba, A, Sullivan, I, Serra-López, J, Cantó, E, Vidal, S, Majem, M. Potential Role of Circulating PD-L1⁺ Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients. Biomedicines. 2024; 12(5)DOI:10.3390/biomedicines12050958. PMID:38790920. IF:3.900(Q1/3D).

01/05/2024 Kinetics of IFN?-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors

Alserawan, L, Mulet, M, Anguera, G, Riudavets, M, Zamora, C, Osuna-Gómez, R, Serra-López, J, Joaquín, AB, Sullivan, I, Majem, M, Vidal, S. Kinetics of IFN?-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors. Cancers. 2024; 16(9)DOI:10.3390/cancers16091759. PMID:38730712. IF:4.400(Q2/3D).

01/05/2024 Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer

Riudavets, M, Auclin, E, Mosteiro, M, Dempsey, N, Majem, M, Prelaj, A, López-Castro, R, Bosch-Barrera, J, Pilotto, S, Escalera, E, Tagliamento, M, Mosquera, J, Zalcman, G, Nana, FA, Ponce, S, Albarrán-Artahona, V, Dal Maso, A, Spotti, M, Mielgo, X, Mussat, E, Reyes, R, Benítez, JC, Lupinacci, L, Duchemann, B, De Giglio, A, Blaquier, JB, Audigier-Valette, C, Scheffler, M, Nadal, E, Lopes, G, Signorelli, D, Garcia-Campelo, R, Menis, J, Bluthgen, V, Campayo, M, Recondo, G, Besse, B, Mezquita, L, Planchard, D. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer. Clinical Lung Cancer. 2024; 25(3)DOI:10.1016/j.cllc.2023.11.007. PMID:38105153. IF:3.300(Q2/4D).

22/04/2024 Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer

Torres-Esquius, S, Llop-Guevara, A, Gutiérrez-Enríquez, S, Romey, M, Teulé, A, Llort, G, Herrero, A, Sánchez-Henarejos, P, Vallmajó, A, González-Santiago, S, Chirivella, I, Cano, JM, Graña, B, Simonetti, S, de Corcuera, ID, Cajal, TRY, Sanz, J, Serrano, S, Otero, A, Churruca, C, Sánchez-Heras, AB, Servitja, S, Guillén-Ponce, C, Brunet, J, Denkert, C, Serra, V, Balmaña, J. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer. JAMA Network Open. 2024; 7(4)DOI:10.1001/jamanetworkopen.2024.7811. PMID:38648056. IF:9.700(Q1/1D).

18/04/2024 MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations

Lubinski, J, Kotsopoulos, J, Moller, P, Pal, T, Eisen, A, Peck, L, Karlan, BY, Aeilts, A, Eng, C, Bordeleau, L, Foulkes, WD, Tung, N, Couch, FJ, Fruscio, R, Cajal, T, Singer, CF, Neuhausen, SL, Zakalik, D, Cybulski, C, Gronwald, J, Huzarski, T, Stempa, K, Dungan, J, Cullinane, C, Olopade, OI, Metcalfe, K, Sun, P, Narod, SA. MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations. JAMA Oncology. 2024; DOI:10.1001/jamaoncol.2023.6944. PMID:38421676. IF:20.100(Q1/1D).

10/04/2024 Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Motzer, RJ, Porta, C, Eto, M, Powles, T, Gruenwald, V, Hutson, TE, Alekseev, B, Rha, SY, Merchan, J, Goh, JC, Lalani, AKA, De Giorgi, U, Melichar, B, Hong, SH, Gurney, H, Mendez-Vidal, MJ, Kopyltsov, E, Tjulandin, S, Gordoa, TA, Kozlov, V, Alyasova, A, Winquist, E, Maroto, P, Kim, M, Peer, A, Procopio, G, Takagi, T, Wong, SR, Bedke, J, Schmidinger, M, Rodriguez-Lopez, K, Burgents, J, He, CX, Okpara, CE, Mckenzie, J, Choueiri, TK. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(11)DOI:10.1200/JCO.23.01569. PMID:38227898. IF:41.900(Q1/1D).

01/04/2024 Tumor analysis of MMR genes in Lynch-like syndrome: Challenges associated with results interpretation

Rofes, P, Dueñas, N, del Valle, J, Navarro, M, Balmaña, J, Ramón y Cajal, T, Tuset, N, Castillo, C, González, S, Brunet, J, Capellá, G, Lázaro, C, Pineda, M. Tumor analysis of MMR genes in Lynch-like syndrome: Challenges associated with results interpretation. Cancer Medicine. 2024; 13(7)DOI:10.1002/cam4.7041. PMID:38558366. IF:3.100(Q2/5D).

21/03/2024 The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Rueda, AG, Taus, A, Alvarez, RA, Bernabé-Caro, R, Chara, L, López-Brea, M, Vilà, L, González, MAS, Aldagalán, ADD, Herrera, BE, Castro, RL, Cabellos, RA, Doménech, M, Falagan, S, Vega, AM, Aguado, C, Barba, A, Ureña, MTD, Isla, D, Hernández, LB, Pérez, JLF, Juan-Vidal, O, Massuti, B, Mielgo-Rubio, X, Ortega, AL, Catot, S, Dómine, M, Escoín-Pérez, C, Navalón, FG, Gil-Bazo, I, Muñoz, S, Rodríguez-Abreu, D, Roldán, RMV, Curbera, GA, León-Mateos, L, Padilla, A, Lario, AP, Sánchez-Torres, JM, Garrido, P. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Clinical & Translational Oncology. 2024; 26(9)DOI:10.1007/s12094-024-03404-9. PMID:38512450. IF:2.500(Q3/6D).

01/03/2024 A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)

Di Giacomo, AM, Schenker, M, Medioni, J, Mandziuk, S, Majem, M, Gravis, G, Cornfeld, M, Ranganathan, S, Lou, S, Csoszi, T. A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203). ESMO Open. 2024; 9(3)DOI:10.1016/j.esmoop.2024.102387. PMID:38401247. IF:8.300(Q1/2D).

01/03/2024 Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023)

Grünwald, V, Powles, T, Eto, M, Kopyltsov, E, Rha, SY, Porta, C, Motzer, R, Hutson, TE, Méndez-Vidal, MJ, Hong, SH, Winquist, E, Goh, JC, Maroto, P, Buchler, T, Takagi, T, Burgents, JE, Perini, R, He, CX, Okpara, CE, McKenzie, J, Choueiri, TK. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023). Frontiers in Oncology. 2024; 13DOI:10.3389/fonc.2023.1343027. PMID:38495081. IF:3.300(Q2/4D).

01/03/2024 What About Variant Histologies in Bladder Cancer?

Day, E, Gavira, J, Tapia, JC, Anguera, G, Maroto, P. What About Variant Histologies in Bladder Cancer?. European Urology Focus. 2024; 10(2)DOI:10.1016/j.euf.2024.05.015. PMID:38849276. IF:5.600(Q1/1D).

01/02/2024 The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families

Schreurs, MAC, Cajal, TRY, Adank, MA, Collee, JM, Hollestelle, A, van Rooij, J, Schmidt, MK, Hooning, MJ. The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families. BREAST. 2024; 73DOI:10.1016/j.breast.2023.103611. PMID:38039887. IF:7.900(Q1/1D).

01/02/2024 Peapod FOS trial: A phase 2 clinical trial of pembrolizumab in combination with carboplatin and cabazitaxel in aggressive variant metastatic castration-resistant prostate cancer.

Villarrubia, JE, Gordoa, TA, Mellado-González, B, Duran, I, Pinto, A, Sanchez, A, Pous, AF, Vazquez-Estevez, S, Puente, J, Grande, E, Climent, MA, Maroto-Rey, P, Perez-Gracia, JL, Aix, SP, Castellano, D, Gonzalez-Billalabeitia, E. Peapod FOS trial: A phase 2 clinical trial of pembrolizumab in combination with carboplatin and cabazitaxel in aggressive variant metastatic castration-resistant prostate cancer.. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(4_SUPPL)DOI:10.1200/JCO.2024.42.4_suppl.TPS238. PMID:. IF:41.900(Q1/1D).

20/01/2024 Nutritional impact and prognostic role of systemic inflammatory response index (SIRI) in advanced pancreatic cancer: PANTHEIA-Spanish Society of Medical Oncology (SEOM) study results.

Pacheco-Barcia, V, Méndez, AM, Carmona-Bayonas, A, Gallego, J, Franco, CF, Adeva, J, Cerdà, P, Cabezon-Gutierrez, L, Custodio-Cabello, S, Ghanem, I, Hernandez, I, Lamarca, A, Laquente, B, López-Alfonso, A, Lago, NM, Macarulla, T, Peiro, I, Visa, L, Jimenez-Fonseca, P, Muñoz, A. Nutritional impact and prognostic role of systemic inflammatory response index (SIRI) in advanced pancreatic cancer: PANTHEIA-Spanish Society of Medical Oncology (SEOM) study results.. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(3_SUPPL)DOI:10.1200/JCO.2024.42.3_suppl.623. PMID:. IF:41.900(Q1/1D).

20/01/2024 Health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) treated with sotorasib and panitumumab (pmab) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in CodeBreaK 300.

Modest, DP, Fakih, M, Salvatore, L, Esaki, T, Lopez-Bravo, DP, Taieb, J, Karamouzis, M, Ruiz-Garcia, E, Kim, TW, Kuboki, Y, Meriggi, F, Cunningham, D, Yeh, KH, Cremolini, C, Tran, Q, Chan, E, Chao, J, Majer, IM, Pietrantonio, F. Health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) treated with sotorasib and panitumumab (pmab) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in CodeBreaK 300.. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(3_SUPPL)DOI:10.1200/JCO.2024.42.3_suppl.10. PMID:. IF:41.900(Q1/1D).

08/01/2024 Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?

Contreras-Toledo, D, Jiménez-Fonseca, P, López, CL, Montes, AF, Muñoz, AML, Rivera, FV, Alonso, V, Alcaide, J, Salvà, F, Rúa, MC, Guillot, M, Carnicero, AM, Mate, RJ, García, SC, Martínez, EA, Astorga, BG, Fernandez-Diaz, AB, Villaroel, PG, Manrique, ACV, Sosa, MM, Alonso, B, Castiñeiras, AC, López, CC, Aparicio, J, Carmona-Bayonas, A. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?. BRITISH JOURNAL OF CANCER. 2024; 130(5)DOI:10.1038/s41416-023-02563-w. PMID:38191609. IF:6.800(Q1/2D).

04/01/2024 Capecitabine-Related Thrombotic Microangiopathy

Mateo, FJP, Guasch, AD, Pineda, JAG, Manrique, ACV, Cullell, BM, López-Bravo, DP, Díaz, JG, Cascón, AP, Freiria, XB. Capecitabine-Related Thrombotic Microangiopathy. Journal Of Gastrointestinal Cancer. 2024; 55(2)DOI:10.1007/s12029-023-00993-6. PMID:38175385. IF:(Q/D).

01/01/2024 Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review

Shachar, SS, Korzets, Y, Shepshelovich, D, Zlothover, N, Amir, E, Tibau, A, Goldvaser, H. Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review. CANCER TREATMENT REVIEWS. 2024; 122DOI:10.1016/j.ctrv.2023.102666. PMID:38064877. IF:10.500(Q1/1D).

01/01/2024 Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

Grünwald, V, Powles, T, Eto, M, Kopyltsov, E, Rha, SY, Porta, C, Motzer, R, Hutson, TE, Méndez-Vidal, MJ, Hong, SH, Winquist, E, Goh, JC, Maroto, P, Buchler, T, Takagi, T, Burgents, JE, Perini, R, He, C, Okpara, CE, McKenzie, J, Choueiri, TK. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Onkourologiya. 2024; 20(1)DOI:10.17650/1726-9776-2024-20-1-24-35. PMID:. IF:(Q/D).

20/10/2023 Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

Ahn, MJ, Cho, BC, Felip, E, Korantzis, I, Ohashi, K, Majem, M, Juan-Vidal, O, Handzhiev, S, Izumi, H, Lee, JS, Dziadziuszko, R, Wolf, J, Blackhall, F, Reck, M, Alvarez, JB, Hummel, HD, Dingemans, AMC, Sands, J, Akamatsu, H, Owonikoko, TK, Ramalingam, SS, Borghaei, H, Johnson, ML, Huang, S, Mukherjee, S, Minocha, M, Jiang, TY, Martinez, P, Anderson, ES, Paz-Ares, L. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE. 2023; 389(22)DOI:10.1056/NEJMoa2307980. PMID:37861218. IF:96.300(Q1/1D).

31/12/2025 Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)

Rodero, BS, Martínez-Toledo, C, Nadal, E, Molina-Alejandre, M, Campelo, RG, Gil-González, A, Massuti, B, García-Grande, A, Dómine, M, Insa, A, Carpeño, JD, Vence, GH, Majem, M, Martinez-Marti, A, Megias, D, Lobato, D, Collazo-Lorduy, A, Calvo, V, Provencio, M, Cruz-Bermúdez, A. Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial). OncoImmunology. 2025; 14(1)DOI:10.1080/2162402X.2025.2513109. PMID:40468805. IF:6.300(Q1/2D).

01/12/2025 Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study

Cerezuela-Fuentes, P, de la Rosa, CA, Crespo, G, Berciano-Guerrero, MA, Soria, A, Muñoz-Couselo, E, Castro, RL, Majem, M, de Miguel, PA, Manzano, JL, Bellido, L, Lecumberri, MJ, Subias, MC, Guzmán, JCV, Hernández, B, Espinosa, E, Puértolas, T, Sanz, LG, Martínez, JM, Abril, VP, Algarra, SM, Márquez-Rodas, I. Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study. MELANOMA RESEARCH. 2025; 35(6)DOI:10.1097/CMR.0000000000001062. PMID:40901826. IF:1.900(Q3/6D).

15/11/2025 Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial

Hecht, JR, Park, YS, Tabernero, J, Lee, MA, Lee, SHY, Virgili, AC, van den Eynde, M, Fontana, E, Fakih, M, Asghari, G, So, JE, Stein, A, Dubreuil, O, Bodnar, L, He, CS, Wang, G, Smith, R, Eng, C, Saeed, A. Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial. LANCET. 2025; 406(10517)DOI:10.1016/S0140-6736(25)02025-2. PMID:41130252. IF:88.500(Q1/1D).

12/11/2025 Mammographic density and breast cancer pathological subtypes by menopausal status and body mass index (vol 27, 187, 2025)

Fernández-Morata, J, Pollán, M, de Larrea-Baz, NF, Pachon-Olmos, V, García-Pérez, J, Castello, A, Sierra, MA, Lucas, P, Llobet, R, Stradella, A, Cantos, B, Cajal, TRY, Santisteban, M, Seguí, MA, Bertrán, AS, Granja, M, Camps-Herrero, J, Recalde, S, Nuñez-García, B, Verges, NC, Pérez-Gomez, B, Pastor-Barriuso, R, Lope, V. Mammographic density and breast cancer pathological subtypes by menopausal status and body mass index (vol 27, 187, 2025). BREAST CANCER RESEARCH. 2025; 27(1)DOI:10.1186/s13058-025-02169-5. PMID:41225573. IF:5.600(Q1/2D).

01/11/2025 Novel approaches for the discovery of pharmacogenetic biomarkers of chemotoxicity in patients with colorectal cancer

Simoes, AR, González, SC, Lopez-Doldan, MD, Duran, G, Fernández-Montes, A, Fernandez, MP, Fernandez, MS, Mata, JG, Paez, D, Riera, P, Guino, E, Lopez-Fernandez, L, de Santiago, BG, Aspiroz, EL, Rojas, A, Castells, A, Castellvi-Bel, S, Ponte, CR, Vymetalkova, V, Carracedo, A, Fernandez-Rozadilla, C. Novel approaches for the discovery of pharmacogenetic biomarkers of chemotoxicity in patients with colorectal cancer. BRITISH JOURNAL OF PHARMACOLOGY. 2025; 182(21)DOI:10.1111/bph.70051. PMID:40624839. IF:7.700(Q1/1D).

01/11/2025 Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial

Isla, D, Zugazagoitia, J, Arriola, E, García-Campelo, R, Blanco, CM, Diz-Taín, MP, Lopez-Brea, M, Moreno-Vega, AL, León-Mateos, L, Oramás, J, Gutiérrez-Calderón, V, Majem, M, Sánchez-Hernández, A, Aguado, C, Alvarez-Cabellos, R, Massutí, B, Moreno, A, Fírvida-Pérez, JL, Valdivia, J, González-Cordero, M, Zafra-Poves, M, Dómine, M, Garcia-Navalon, FJ, Villanueva, N, Provencio, M, Juan-Vidal, O, Rivas-Corredor, C, García, MEO, Palmero, R, López-Castro, R, Carcereny, E, Lechuga, JL, Domínguez, M, Callejo, A, Paz-Ares, L. Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial. LUNG CANCER. 2025; 209DOI:10.1016/j.lungcan.2025.108763. PMID:41033130. IF:4.400(Q1/2D).

01/11/2025 Predictive factors of efficacy for FTD/TPI plus bevacizumab in refractory metastatic colorectal cancer patients: a subanalysis of the Spanish cohort from the SUNLIGHT phase III trial

Soler, G, Grávalos, C, Rivera, F, Safont, MJ, Virgili, AC, Valladares-Ayerbes, M, Ferreiro-Monteagudo, R, Ortiz-Morales, MJ, Polo-Marques, E, Kornusova-Bersheva, I, Soustre, E, Yao, WY, Élez, E. Predictive factors of efficacy for FTD/TPI plus bevacizumab in refractory metastatic colorectal cancer patients: a subanalysis of the Spanish cohort from the SUNLIGHT phase III trial. Clinical & Translational Oncology. 2025; 27(11)DOI:10.1007/s12094-025-03907-z. PMID:40338282. IF:2.500(Q3/6D).

01/11/2025 Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression = 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

Cortellini, A, Garbo, E, La Cava, G, Citarella, F, Santo, V, Brunetti, L, Pinato, DJ, Naidoo, J, Loza, M, Genova, C, Gettinger, S, Kim, SY, Jayakrishnan, R, El Zarif, T, Russano, M, Pecci, F, Di Federico, A, Montrone, M, Owen, DH, Signorelli, D, Li, MJ, Camerini, A, Halmos, B, Vincenzi, B, Metro, G, Yendamuri, S, Grossi, F, Josephides, E, Tomasik, B, Giusti, R, Bria, E, Sebastian, M, Rost, M, Acker, F, Landi, L, Mazzoni, F, Morabito, A, Leonetti, A, Cantini, L, Mountzios, G, Kalvapudi, S, O'Reilly, D, Karapanagiotou, E, Monnet, I, Baena, J, Macerelli, M, Majem, M, Piedra, A, Cortinovis, DL, Tonini, G, Minuti, G, Mezquita, L, Gorria, T, Beninato, T, Lo Russo, G, Prelaj, A, De Giglio, A, Biello, F, Nana, FA, Dingemans, AMC, Aerts, JG, Ferrara, R, Abu Hejleh, T, Takada, K, Naqash, AR, Garassino, MC, Wakelee, HA, Nassar, A, Ricciuti, B, Soda, P, Caruso, CM, Guarrasi, V. Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression = 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity. LUNG CANCER. 2025; 209DOI:10.1016/j.lungcan.2025.108799. PMID:41108882. IF:4.400(Q1/2D).

10/10/2025 Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)

Yang, JCH, Wang, MZ, Doucet, L, Fan, Y, Lv, DQ, Sun, ML, Huang, DZ, Greillier, L, Planchard, D, Hong, QY, Mazieres, J, Felip, E, Li, XY, Hu, Y, Fang, J, Bazhenova, L, Ghiringhelli, F, Dols, MAC, Rodriguez, LPA, Bearz, A, Pellini, B, Kim, YJ, Bosch-Barrera, J, Shim, BY, Luo, YH, Tiseo, M, Yang, TY, Carcereny, E, Memmott, RM, Zalcman, G, Carpeno, JD, Di Noia, V, Parra, HS, Streich, G, Lee, DH, Shum, E, Han, JY, Jaime, JC, Brungs, D, John, T, D'Arcangelo, M, Joaquin, AB, Liu, GF, Antonuzzo, L, Hinojal, GF, Le, XN, Zheng, L, Jänne, PA. Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(29)DOI:10.1200/JCO-25-00788. PMID:40923280. IF:41.900(Q1/1D).

01/10/2025 Oncological needs in transgender patients

de la Peña, FA, Martínez-Ramos, D, Juan-Vidal, O, Gómez-Balaguer, M, Miguélez, M, Páez, D, Arrazubi, V, González, CH. Oncological needs in transgender patients. Clinical & Translational Oncology. 2025; 27(10)DOI:10.1007/s12094-025-03917-x. PMID:40251439. IF:2.500(Q3/6D).

01/10/2025 Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study

Suárez, C, Torras, OR, Barrera, RM, Sánchez, AR, Palacios, GA, Manshino, AMB, Núñez, NF, Vidal, MJM, Carbonero, IG, Calvo, OF, Sarrió, RG, Herrero, GC, Afonso, JA, Fita, MJJ, Padró, JG, Quintela, ML, Rodriguez-Vida, A, Perez, CH, Colmenero, AM, Martin, RC, de España, CG, Palau, CM, Ortega, EM, Gallardo, E. Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study. Clinical Genitourinary Cancer. 2025; 23(5)DOI:10.1016/j.clgc.2025.102402. PMID:40830022. IF:2.700(Q2/3D).

01/10/2025 Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials

Palmerini, E, Meazza, C, Tamburini, A, Márquez-Vega, C, Bisogno, G, Fagioli, F, Ferraresi, V, Milano, GM, Coccoli, L, Rubio-San-Simón, A, Gallego, O, Riestra, MEL, Manzitti, C, Mora, J, Vaz-Salgado, MA, Luksch, R, Mata, C, Pierini, M, Carretta, E, Cesari, M, Paioli, A, Marrari, A, Scotlandi, K, Serra, M, Asaftei, SD, Gambarotti, M, Picci, P, Ferrari, S, Valverde, C, Ibrahim, T, Broto, JM. Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(28)DOI:10.1200/JCO-25-00210. PMID:40825172. IF:41.900(Q1/1D).